Concepedia

Michael Seiberling

MS

Statistics

Publications

29

Citations

1.9K

H-Index

21

Active since

1987

Affiliations

Novartis (Switzerland)(Current)

Vifor Pharma (Switzerland)

Novartis (United States)

Covance (United States)

Novartis (France)

Michael Seiberling is an author at Novartis (Switzerland) specializing in pharmacokinetics, pharmacology, and clinical pharmacology.

Publications per year

1987–2013

29

Publications

29

METABOLISM AND DISPOSITION OF IMATINIB MESYLATE IN HEALTHY VOLUNTEERS

Hans-Peter Gschwind, Ulrike Pfaar, Felix Waldmeier et al. · Drug Metabolism and Disposition · 2005 · 221 citations

, , +15

Absolute Bioavailability of Imatinib (Glivec®) Orally versus Intravenous Infusion

Bin Peng, Catherine Dutreix, Günther H. Mehring et al. · The Journal of Clinical Pharmacology · 2004 · 167 citations

, , +17

Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects

Ann E. Bolton, Bin Peng, Martine Hubert et al. · Cancer Chemotherapy and Pharmacology · 2004 · 159 citations

, , +6

Pharmacokinetic interaction between ketoconazole and imatinib mesylate (Glivec) in healthy subjects

Catherine Dutreix, Bin Peng, Guenther H. Mehring et al. · Cancer Chemotherapy and Pharmacology · 2004 · 154 citations

, , +10

Absorption, Distribution, Metabolism, and Elimination of the Direct Renin Inhibitor Aliskiren in Healthy Volunteers

Felix Waldmeier, Ulrike Glaenzel, B. Wirz et al. · Drug Metabolism and Disposition · 2007 · 127 citations

, , +16

1–5 of 29